43 completed, 12 terminated, 3 recruiting, 2 withdrawn. 31 Phase 2, 26 Phase 1, 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 21, Terminated 8, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 26 | Completed 18, Terminated 6, Withdrawn 2 |
| Phase 3 | 14 | Completed 8, Terminated 4, Recruiting 2 |
Follow Nektar Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Rezpegaldesleukin, Placebo - Moderate-to-Severe Atopic Dermatitis | Phase 3 | Recruiting | Nektar Therapeutics | 510 | 2026-08-07 | 2026-09-08 |
| A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Rezpegaldesleukin, Placebo - Moderate-to-Severe Atopic Dermatitis | Phase 3 | Recruiting | Nektar Therapeutics | 510 | 2026-06-29 | 2026-10-21 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) Rezpegaldesleukin, Placebo - Alopecia Areata | Phase 2 | Completed | Nektar Therapeutics | 94 | 2024-04-02 | 2026-09-18 |
| C-TIL051 in Non-Small Cell Lung Cancer C-TIL051 - Metastatic Non Small Cell Lung Cancer | Phase 1 | Terminated | AbelZeta Inc. | 1 | 2024-02-29 | 2026-01-05 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Rezpegaldesleukin, Placebo - Moderate to Severe Atopic Dermatitis | Phase 2 | Active not recruiting | Nektar Therapeutics | 396 | 2023-11-15 | 2026-08-21 |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg - Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Terminated | Nektar Therapeutics | 15 | 2023-02-23 | 2026-10-16 |
| REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) NKTR-255, Durvalumab - Lung Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 39 | 2023-01-10 | 2026-07-29 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| A Phase I Study of LY3471851 in Healthy Participants LY3471851, Placebo, Levocetirizine - Healthy | Phase 1 | Completed | Nektar Therapeutics | 41 | 2022-10-05 | 2023-11-18 |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Bempegaldesleukin, Pembrolizumab - Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 / Phase 3 | Terminated | Nektar Therapeutics | 1 | 2022-03-09 | 2023-01-12 |
| A Single-Dose Study of LY3471851 in Healthy Participants LY3471851 - Healthy | Phase 1 | Completed | Nektar Therapeutics | 71 | 2021-08-16 | 2023-11-18 |
| Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma NKTR-214, anti-PD-1 therapy, Palliative Radiation - Head and Neck Cancer | Phase 2 | Terminated | University of Wisconsin, Madison | 5 | 2021-08-05 | 2024-04-04 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 15 | 2021-06-03 | 2023-03-24 |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) LY3471851, Placebo - Colitis, Ulcerative | Phase 2 | Terminated | Nektar Therapeutics | 81 | 2021-03-22 | 2023-09-05 |
| A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Bempegaldesleukin, Standard of Care, Placebo - Covid-19, Coronavirus Disease 2019 | Phase 1 | Completed | Nektar Therapeutics | 30 | 2020-11-13 | 2024-03-12 |
| Study of NKTR 255 in Combination With Cetuximab in Solid Tumors NKTR-255, Cetuximab - Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Nektar Therapeutics | 25 | 2020-10-30 | 2025-06-08 |
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread Nivolumab, Axitinib, Cabozantinib - Renal Cell Carcinoma | Phase 1 | Completed | Bristol-Myers Squibb | 30 | 2020-09-11 | 2024-02-28 |
| A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) LY3471851, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | Nektar Therapeutics | 291 | 2020-08-19 | 2024-04-23 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Bempegaldesleukin, Nivolumab - Melanoma, Melanoma Stage III | Phase 3 | Terminated | Nektar Therapeutics | 765 | 2020-07-27 | 2023-04-21 |
| A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Nivolumab, Radical cystectomy (RC), Bempegaldesleukin - Bladder Cancer, Bladder Tumor | Phase 3 | Completed | Bristol-Myers Squibb | 114 | 2020-02-05 | 2024-06-27 |
Showing 20 of 61. Sign in to see all of them.
Melanoma (7) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Non-Hodgkin (4) · Neoplasm Metastasis (4) · Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Recurrence (3) · Carcinoma, Transitional Cell (2) · Chronic Pain (2) · Head and Neck Neoplasms (2) · Low Back Pain (2) · Lupus Erythematosus, Systemic (2)
bempegaldesleukin (18) · Nivolumab (11) · etirinotecan pegol (10) · NKTR-255 (5) · pembrolizumab (4) · Paclitaxel (3) · Carboplatin (2) · Cetuximab (2) · Cisplatin (2) · NKTR-181 (2) · Pemetrexed (2) · cabozantinib (2) · rhoA GTP-Binding Protein (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1)
United States (59) · Canada (14) · Spain (14) · France (13) · Australia (12) · Belgium (12) · Germany (12) · United Kingdom (11) · Italy (9) · Poland (9) · Russia (9) · Argentina (7) · Czechia (7) · Israel (7) · Mexico (7)
Alison Hannah, MD (2) · Ivan Gergel, MD (2) · Adam Burr, MD, PhD (1) · Alexandre Hirayama (1) · Hongbin Chen, MD (1) · Joel Neal (1) · Justine Bruce, MD (1) · Lawrence Recht, MD (1) · Lucy B Palmer, MD (1) · Mark Sostek (1)
PMID 30957581, PMID 39455575, PMID 41811823, PMID 20003269, PMID 22147112, PMID 24095299, PMID 26482278, PMID 28360015, PMID 28612225, PMID 28935273, PMID 30747908, PMID 30988166, PMID 31074641, PMID 31866328, PMID 32723187, PMID 33298619, PMID 34001523, PMID 34154392, PMID 34255535, PMID 34311780, PMID 35073733, PMID 35444059, PMID 35552364, PMID 35643589, PMID 37651676, PMID 38838287, PMID 40877204, PMID 42628554
2018 (5), 2019 (2), 2025 (2), 2016 (1), 2023 (1), P30CA016056 (1)